Adams Diversified Equity Fund Inc. Sells 13,500 Shares of ChemoCentryx, Inc. (NASDAQ:CCXI)
Adams Diversified Equity Fund Inc. decreased its position in ChemoCentryx, Inc. (NASDAQ:CCXI) by 15.4% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 74,400 shares of the biopharmaceutical company’s stock after selling 13,500 shares during the period. Adams Diversified Equity Fund Inc. owned 0.15% of ChemoCentryx worth $696,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently bought and sold shares of the company. Bank of Montreal Can acquired a new stake in ChemoCentryx during the second quarter valued at approximately $102,000. First Quadrant L P CA acquired a new stake in ChemoCentryx during the second quarter valued at approximately $219,000. Dynamic Technology Lab Private Ltd acquired a new stake in ChemoCentryx during the first quarter valued at approximately $189,000. Teachers Advisors LLC boosted its stake in ChemoCentryx by 8.4% in the fourth quarter. Teachers Advisors LLC now owns 40,288 shares of the biopharmaceutical company’s stock valued at $298,000 after buying an additional 3,114 shares in the last quarter. Finally, American Century Companies Inc. acquired a new stake in ChemoCentryx during the first quarter valued at approximately $297,000. 49.57% of the stock is owned by institutional investors.
ChemoCentryx, Inc. (NASDAQ:CCXI) opened at 10.39 on Monday. ChemoCentryx, Inc. has a 1-year low of $3.95 and a 1-year high of $10.80. The company has a 50 day moving average price of $9.21 and a 200 day moving average price of $7.62. The firm’s market cap is $500.52 million.
ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.14. The business had revenue of $8.23 million during the quarter. On average, equities research analysts forecast that ChemoCentryx, Inc. will post ($0.69) earnings per share for the current year.
Separately, Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Monday, July 17th.
In related news, insider Petrus Bekker sold 76,013 shares of the stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $9.95, for a total transaction of $756,329.35. Following the transaction, the insider now directly owns 65,963 shares of the company’s stock, valued at $656,331.85. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 223,649 shares of company stock valued at $2,157,360. 26.80% of the stock is currently owned by corporate insiders.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Stock Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related stocks with our FREE daily email newsletter.